My thought are.
No trifecta but a very good Double.
1/Response rate was Higher with sirt by 7.4%
2/Both the side effect profile and QUALITY OF LIFE was much better over time in the sirt group.
3/ if patient Re not tolerant or have contraindications for Sorafenib therapy there are currently no standard of care .
Paragraph 2 an 3 is the key for me.
Yes i get it the primary end point did not show an overall survival superiority
I the end quality of life is far more important.
Glta
Sirt result
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.005(4.35%) |
Mkt cap ! $50.93M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 11.0¢ | $373.6K | 3.191M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 504724 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 373819 | 5 |
View Market Depth
| Last trade - 15.05pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.5¢ | 12.5¢ | 11.5¢ | 193650 | ||
| Last updated 15.02pm 02/05/2024 ? | |||||
| SRX (ASX) Chart |